PF Warriors

Important Update for PF Patients & Caregivers: Medicare Telehealth Extension Medicare has extended telehealth appointment coverage through March 31, 2025 (previously set to end on December 31, 2025). If you have telehealth appointments scheduled beyond this date, be sure to check with your healthcare provider to understand how this may affect your care. Staying informed about coverage changes helps ensure uninterrupted access to the care you need. For the most up-to-date information, your healthcare provider, Medicare, or insurance provider can provide guidance on how this extension applies to your situation.

With the arrival of daylight savings time, we lost an hour of sleep which makes National Napping Day the perfect time to share this article on why sleep is so important from the National Institutes of Health! ??????

PF Warriors is excited to invite you to a special Zoom clinical trial presentation. Join us to learn about MIST, a phase 2b study for people living with progressive pulmonary fibrosis (PPF). ??? Thursday, March 13, 2025 ?? 10:00 am Central Time (US) ?? Online via Zoom REGISTER TODAY! https://bit.ly/MIST2025 Topics to be discussed: 1. Introduction to Avalyn Pharma 2. A brief review of data from prior studies with Pirfenidone Solution for Inhalation 3. Overview of the MIST 2b Study, including qualification criteria and information on locating study sites A short Q&A session with Craig Conoscenti,MD,FCCP,ATSF, and Rebecca Weaver, APRN will follow the presentation. Please email your questions in advance to [email protected] REGISTER TODAY! https://bit.ly/MIST2025

"The discontinuation of the BEACON-IPF trial is disappointing news for the pulmonary fibrosis community. While the trial’s early signs of efficacy are encouraging, the safety concerns highlight the complexities of developing new treatments for IPF. We appreciate the dedication of the researchers, trial participants, and their families, and we remain hopeful that the insights gained from this study will inform future advancements in the fight against IPF. We thank Pliant Therapeutics for their commitment to IPF research. PF Warriors remains committed to supporting patients and advocating for continued innovation in pulmonary fibrosis treatment." -- Dolly Kervitsky, RCP, CCRC, CNP President, PF Warriors Read the full Pliant Therapeutics release here: https://lnkd.in/gyU8dFsS

???? The Critical Role of Testing in Pulmonary Fibrosis Care For individuals living with interstitial lung disease (ILD) or pulmonary fibrosis (PF), routine testing is essential for monitoring disease progression and guiding treatment decisions. But what do these tests reveal, and why are they so important? Join Dr. Evans R. Fernandez, MD, MS, of National Jewish Health for an in-depth discussion on key diagnostic and monitoring tools, including: ?? Pulmonary Function Testing (PFT) ?? Six-Minute Walk Test (6MWT) ?? High-Resolution Computed Tomography (HRCT) This session will explore how these tests inform treatment strategies, impact long-term disease management, and support better patient outcomes. A live Q&A will follow, and attendees are encouraged to submit questions in advance to [email protected]. #PulmonaryFibrosis #LungHealth #PFWarriors

"Collaboration is essential to driving meaningful change for those living with [IPF]. PF Warriors is excited to join forces with CHEST and its partners to enhance IPF awareness, improve diagnosis and care, and address unmet needs in the respiratory community. Together, we are ensuring every patient has access to the resources and support they need. - Dolly Kervitsky, President, PF Warriors ???? American College of Chest Physicians Rare Disease Diversity Coalition National Association of Community Health Centers (NACHC) Teresa Barnes Theresa Genovese Tom Tully Christian Gomez Bill Vick

Join us for our February PF Warriors Q&A meeting. This monthly session is led by patients and caregivers. Ask questions and learn more about living with pulmonary fibrosis (PF). ??? Thursday, February 27, 2025 ?? 10am Central Time (US) Register TODAY! https://bit.ly/W2WFEB2025 We, as patients and caregivers, are here to support and help each other. Whether you have questions or can contribute answers, your presence is valuable. Do you have questions? Email your questions ahead of the meeting to [email protected]

?? Oxygen Concentrator Recall: JIANGSU JUMAO X-CARE MEDICAL EQUIPMENT CO LTD Removes JMC5A Ni/TruAire-5 Oxygen Concentrator due to the devices spontaneously catching fire via FDA This recall involves removing devices from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it. Affected Product JMC5A Ni/TruAire-5 Oxygen Concentrator Product Names: TRUAIRE-5 02 CONCENTRATOR Model: O2C5L Serial Numbers: All units within serial number range: JA2311000001-JA2312000740

PR Improves Survival At Five Years In Patients With ILD, Study Suggests Pulmonology Advisor (2/11, Stong) reports, “Pulmonary rehabilitation (PR) may improve survival at 5 years in patients with interstitial lung disease (ILD), according to study findings.” The researchers said, “This secondary analysis of [randomized controlled trial] data demonstrated that PR may positively impact 5-year survival in people with ILD, strengthening the recommendation for PR to be part of the standard and holistic care of people with ILD.” The findings were published in American College of Chest Physicians. "These findings reinforce what we’ve long believed—pulmonary rehabilitation is a vital part of comprehensive ILD care. While not a cure, it can improve quality of life, making it an essential tool for patients and their care teams." - Dolly Kervitsky, RCP, CCRC, CNP President, PF Warriors #ILD #PulmonaryRehab #PulmonaryFibrosis

Boehringer Ingelheim’s nerandomilast has successfully met the primary endpoint in the Phase III study FIBRONEER?-ILD for progressive pulmonary fibrosis (PPF). This groundbreaking drug for ILD is now on its way to the FDA for approval! #FDAApproval #BoehringerIngelheim #FIBRONEERILD